Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 926

1.

155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication.

Hassan AO, Vemula SV, Sharma A, Bangari DS, Mishra KK, Mittal SK.

J Gen Virol. 2017 Jan 12. doi: 10.1099/jgv.0.000707. [Epub ahead of print]

PMID:
28086071
2.

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Salazar-Fontana LI, Desai DD, Khan TA, Pillutla RC, Prior S, Ramakrishnan R, Schneider J, Joseph A.

AAPS J. 2017 Jan 12. doi: 10.1208/s12248-016-0030-z. [Epub ahead of print]

PMID:
28083796
3.

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.

El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.

Mol Genet Metab. 2016 Dec 6. pii: S1096-7192(16)30300-6. doi: 10.1016/j.ymgme.2016.12.001. [Epub ahead of print]

4.

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J.

Ann Oncol. 2016 Oct 18. pii: mdw441. doi: 10.1093/annonc/mdw441. [Epub ahead of print]

PMID:
28039155
5.

Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.

Murugesan V, Liu J, Yang R, Lin H, Lischuk A, Pastores G, Zhang X, Chuang WL, Mistry PK.

Blood Cells Mol Dis. 2016 Dec 13. pii: S1079-9796(16)30239-X. doi: 10.1016/j.bcmd.2016.12.002. [Epub ahead of print]

PMID:
28003098
6.

Amplifying Each Patient's Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients.

Marsh K, Caro JJ, Hamed A, Zaiser E.

Appl Health Econ Health Policy. 2016 Dec 7. [Epub ahead of print] Review.

PMID:
27928659
7.

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.

Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010.

8.

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G; CARE-MS I and II Investigators..

Mult Scler. 2016 Nov 1:1352458516677589. doi: 10.1177/1352458516677589. [Epub ahead of print]

PMID:
27885061
9.

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

Valayannopoulos V, Mengel E, Brassier A, Grabowski G.

Mol Genet Metab. 2016 Nov 10. pii: S1096-7192(16)30171-8. doi: 10.1016/j.ymgme.2016.11.002. [Epub ahead of print]

PMID:
27876313
10.

Impact of Copayment Changes on Children's Albuterol Inhaler Use and Costs after the Clean Air Act Chlorofluorocarbon Ban.

Galbraith AA, Fung V, Li L, Butler MG, Nordin JD, Hsu J, Smith D, Vollmer WM, Lieu TA, Soumerai SB, Wu AC.

Health Serv Res. 2016 Nov 20. doi: 10.1111/1475-6773.12615. [Epub ahead of print]

PMID:
27868200
11.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.

Ann Rheum Dis. 2016 Nov 17. pii: annrheumdis-2016-210310. doi: 10.1136/annrheumdis-2016-210310. [Epub ahead of print]

12.

The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage.

Panzitta M, Ponti M, Bruno G, Cois G, D'Arpino A, Minghetti P, Mendicino FR, Perioli L, Ricci M.

Int J Pharm. 2017 Jan 10;516(1-2):144-157. doi: 10.1016/j.ijpharm.2016.11.018.

PMID:
27838294
13.

Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.

Yi H, Zhang Q, Brooks ED, Yang C, Thurberg BL, Kishnani PS, Sun B.

Hum Gene Ther. 2016 Nov 10. [Epub ahead of print]

PMID:
27832700
14.

Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.

Husson H, Moreno S, Smith LA, Smith MM, Russo RJ, Pitstick R, Sergeev M, Ledbetter SR, Bukanov NO, Lane M, Zhang K, Billot K, Carlson G, Shah J, Meijer L, Beier DR, Ibraghimov-Beskrovnaya O.

Hum Mol Genet. 2016 Jun 1;25(11):2245-2255.

15.

Gaucher disease epidemiology and natural history: a comprehensive review of the literature.

Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N.

Hematology. 2016 Oct 20:1-9. [Epub ahead of print]

PMID:
27762169
16.

Glucosylsphingosine is a key biomarker of Gaucher disease.

Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK.

Am J Hematol. 2016 Nov;91(11):1082-1089. doi: 10.1002/ajh.24491.

PMID:
27441734
17.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators..

Neurology. 2016 Nov 8;87(19):1985-1992.

18.

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, Bodrug I, Kivitz A.

Clin Pharmacokinet. 2016 Oct 8. [Epub ahead of print]

PMID:
27722854
19.

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.

Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, Croal LR, Underhill LH, Gaemers SJ, Peterschmitt MJ.

Mol Genet Metab Rep. 2016 Sep 30;9:25-28.

20.

Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.

Liou B, Peng Y, Li R, Inskeep V, Zhang W, Quinn B, Dasgupta N, Blackwood R, Setchell KD, Fleming S, Grabowski GA, Marshall J, Sun Y.

Hum Mol Genet. 2016 Sep 20. pii: ddw322. doi: 10.1093/hmg/ddw322. [Epub ahead of print]

PMID:
27655403
Items per page

Supplemental Content

Loading ...
Support Center